€ million |
|
Note |
|
2021 |
|
2020 |
||||
|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
|
19,687 |
|
17,534 |
|||||
Cost of sales |
|
|
-7,351 |
|
-6,835 |
|||||
Gross profit |
|
|
|
12,335 |
|
10,699 |
||||
|
|
|
|
|
|
|
||||
Marketing and selling expenses |
|
|
-4,304 |
|
-4,207 |
|||||
Administration expenses |
|
|
|
-1,241 |
|
-1,188 |
||||
Research and development costs |
|
|
-2,408 |
|
-2,288 |
|||||
Impairment losses and reversals of impairment losses on financial assets (net) |
|
|
1 |
|
-6 |
|||||
Other operating income |
|
|
528 |
|
838 |
|||||
Other operating expenses |
|
|
-734 |
|
-863 |
|||||
Operating result (EBIT)1 |
|
|
|
4,179 |
|
2,985 |
||||
|
|
|
|
|
|
|
||||
Finance income |
|
|
62 |
|
44 |
|||||
Finance costs |
|
|
-317 |
|
-398 |
|||||
Profit before income tax |
|
|
|
3,924 |
|
2,630 |
||||
|
|
|
|
|
|
|
||||
Income tax |
|
|
-859 |
|
-637 |
|||||
Profit after tax |
|
|
|
3,065 |
|
1,994 |
||||
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany |
|
|
|
3,055 |
|
1,987 |
||||
thereof: attributable to non-controlling interests |
|
|
10 |
|
7 |
|||||
|
|
|
|
|
|
|
||||
Earnings per share (in €) |
|
|
|
|
|
|||||
Basic |
|
|
|
7.03 |
|
4.57 |
||||
Diluted |
|
|
|
7.03 |
|
4.57 |
||||
|
||||||||||